Boston Scientific Enters Deal to Acquire Axonics to Broaden Their Urology Platform

Boston Scientific has entered into a deal to purchase healthcare technology firm Axonics for around $3.7 billion, aiming to broaden its urology platform. 

Axonics concentrates on creating and bringing to market devices designed to address issues related to urinary and bowel function. 

Axonics offers the R20 and F15 devices as part of their product lineup, developed to provide sacral neuromodulation treatment—a solution for fecal incontinence and overactive bladder that is minimally intrusive. 

Meghan Scalon, the chief officer of Boston Scientific urology, stated, “We are excited to add Axonics technologies to the Boston Scientific portfolio, a combination that we expect will further strengthen our ability to serve urologists who are treating patients living with these often-chronic conditions.” 

Raymond Cohen, the chief officer of Axonics, commented, “Our team is looking forward to the global impact we can make as part of Boston Scientific as we endeavour to bring these life-changing therapies to more patients than ever before.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.